Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.

Source:http://linkedlifedata.com/resource/pubmed/id/18818391

Blood 2008 Dec 15 112 13 4839-42

Download in:

View as

General Info

PMID
18818391